ERB-041
Pre-clinicalWithdrawn 1 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystitis, Interstitial
Conditions
Cystitis, Interstitial
Trial Timeline
Aug 1, 2006 → —
NCT ID
NCT00275379About ERB-041
ERB-041 is a pre-clinical stage product being developed by Pfizer for Cystitis, Interstitial. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00275379. Target conditions include Cystitis, Interstitial.
What happened to similar drugs?
2 of 5 similar drugs in Cystitis, Interstitial were approved
Approved (2) Terminated (2) Active (2)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00434187 | Phase 1 | Completed |
| NCT00275379 | Pre-clinical | Withdrawn |
| NCT00316459 | Phase 1 | Completed |
| NCT00318500 | Phase 2 | Completed |
| NCT00110487 | Phase 2 | Completed |
| NCT00245947 | Phase 1 | Completed |
Competing Products
19 competing products in Cystitis, Interstitial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ferumoxytol + Gadobutrol | Lipella Pharmaceuticals | Phase 1 | 19 |
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 25 |
| LP-08 80mg + Normal saline + LP-08 20mg | Lipella Pharmaceuticals | Phase 2 | 25 |
| ASP3652 + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Placebo | Astellas Pharma | Phase 3 | 32 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 42 |
| Placebo + JNJ-42160443 | Johnson & Johnson | Phase 2 | 27 |
| Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg | Johnson & Johnson | Approved | 35 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 2 | 35 |
| Rocuronium | Merck | Approved | 43 |
| Cidofovir | Gilead Sciences | Pre-clinical | 18 |
| PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 | Pfizer | Phase 2 | 35 |
| Tanezumab + Tanezumab + Tanezumab + Tanezumab | Pfizer | Phase 2 | 27 |
| PF-04383119 + Placebo | Pfizer | Phase 2 | 35 |
| Certolizumab pegol + Placebo | UCB | Phase 3 | 40 |
| moxifloxacin | Bayer | Phase 3 | 37 |
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 23 |
| IW-3300 rectal foam + Placebo | Ironwood Pharmaceuticals | Phase 2 | 21 |
| MN-001 BID + MN-001 + Placebo | MediciNova | Phase 2 | 25 |